921 related articles for article (PubMed ID: 17189870)
21. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
Ahmed AB; Mallias J; Home PD
Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
[TBL] [Abstract][Full Text] [Related]
22. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
Päivärinta M; Tapanainen P; Veijola R
Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
[TBL] [Abstract][Full Text] [Related]
23. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
Arutchelvam V; Heise T; Dellweg S; Elbroend B; Minns I; Home PD
Diabet Med; 2009 Oct; 26(10):1027-32. PubMed ID: 19900235
[TBL] [Abstract][Full Text] [Related]
24. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients.
Warren ML; Conway MJ; Klaff LJ; Rosenstock J; Allen E
Diabetes Res Clin Pract; 2004 Oct; 66(1):23-9. PubMed ID: 15364158
[TBL] [Abstract][Full Text] [Related]
25. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
[TBL] [Abstract][Full Text] [Related]
26. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
[TBL] [Abstract][Full Text] [Related]
27. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
[TBL] [Abstract][Full Text] [Related]
28. Dosing of insulin glargine in the treatment of type 2 diabetes.
Barnett A
Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
[TBL] [Abstract][Full Text] [Related]
29. The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes.
Galic E; Vrtovec M; Bozikov V; Schwarzenhofer M; Milicevic Z
Med Sci Monit; 2005 Dec; 11(12):PI87-92. PubMed ID: 16319804
[TBL] [Abstract][Full Text] [Related]
30. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin.
Davies MJ; Thaware PK; Tringham JR; Howe J; Jarvis J; Johnston V; Kitchener DL; Skinner TC; McNally PG; Lawrence IG
Diabet Med; 2007 Jul; 24(7):714-9. PubMed ID: 17403126
[TBL] [Abstract][Full Text] [Related]
31. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.
Luzio S; Peter R; Dunseath GJ; Mustafa L; Owens DR
Diabetes Res Clin Pract; 2008 Feb; 79(2):269-75. PubMed ID: 18164094
[TBL] [Abstract][Full Text] [Related]
32. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.
Ahmed AB; Home PD
Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735
[TBL] [Abstract][Full Text] [Related]
33. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.
Roach P; Bai S; Charbonnel B; Consoli A; Taboga C; Tiengo A; Bolli G;
Clin Ther; 2004 Apr; 26(4):502-10. PubMed ID: 15189747
[TBL] [Abstract][Full Text] [Related]
34. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
Habib SS; Aslam M; Naveed AK; Razi MS
Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
[TBL] [Abstract][Full Text] [Related]
35. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
[TBL] [Abstract][Full Text] [Related]
36. Semilente-insulin at bedtime is superior to NPH-insulin for the suppression of the dawn-phenomenon in adolescents with type-I-diabetes.
Holl RW; Teller WM; Heinze E
Exp Clin Endocrinol Diabetes; 1996; 104(5):360-4. PubMed ID: 8957270
[TBL] [Abstract][Full Text] [Related]
37. Insulin lispro improves postprandial glucose control in patients with diabetes mellitus.
Skrha J; Smahelová A; Andĕl M; Vrtovec M; Subić J; Kreze A; Vozar J; Korecová M; de Verga V; Wyatt J; Metcalfe S; Ristić S
Sb Lek; 2002; 103(1):15-21. PubMed ID: 12448933
[TBL] [Abstract][Full Text] [Related]
38. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM.
Kanc K; Janssen MM; Keulen ET; Jacobs MA; Popp-Snijders C; Snoek FJ; Heine RJ
Diabetologia; 1998 Mar; 41(3):322-9. PubMed ID: 9541173
[TBL] [Abstract][Full Text] [Related]
39. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.
Ashwell SG; Gebbie J; Home PD
Diabet Med; 2006 Aug; 23(8):879-86. PubMed ID: 16911626
[TBL] [Abstract][Full Text] [Related]
40. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
Clements MR; Tits J; Kinsley BT; Råstam J; Friberg HH; Ligthelm RJ
Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
